Banco Bilbao Vizcaya Argentaria S.A. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 559,884 shares of the biopharmaceutical company's stock after selling 30,324 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Gilead Sciences were worth $51,775,000 as of its most recent filing with the SEC.
Several other large investors have also made changes to their positions in GILD. Nicolet Advisory Services LLC increased its stake in shares of Gilead Sciences by 2.9% during the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock valued at $322,000 after purchasing an additional 100 shares in the last quarter. Southland Equity Partners LLC boosted its holdings in shares of Gilead Sciences by 3.6% during the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock valued at $289,000 after acquiring an additional 110 shares during the last quarter. Berkshire Bank lifted its holdings in shares of Gilead Sciences by 3.4% during the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock valued at $314,000 after buying an additional 111 shares during the period. CFO4Life Group LLC increased its position in shares of Gilead Sciences by 2.7% during the 4th quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company's stock valued at $394,000 after purchasing an additional 112 shares during the last quarter. Finally, Howe & Rusling Inc. raised its position in Gilead Sciences by 2.5% in the fourth quarter. Howe & Rusling Inc. now owns 4,704 shares of the biopharmaceutical company's stock worth $435,000 after acquiring an additional 115 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.
Gilead Sciences Stock Performance
Shares of GILD stock traded down $0.15 during mid-day trading on Tuesday, hitting $106.19. 2,601,162 shares of the stock were exchanged, compared to its average volume of 8,902,132. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96. The stock's fifty day simple moving average is $109.19 and its two-hundred day simple moving average is $98.48. The stock has a market capitalization of $132.23 billion, a price-to-earnings ratio of 287.01, a P/E/G ratio of 0.71 and a beta of 0.32.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm's revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.32) EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.
Gilead Sciences Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.98%. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.
Wall Street Analyst Weigh In
GILD has been the subject of a number of analyst reports. The Goldman Sachs Group increased their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Bank of America raised their price target on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a "hold" rating to a "buy" rating and increased their price objective for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Oppenheimer decreased their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday. Finally, BMO Capital Markets upped their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of "Moderate Buy" and an average price target of $109.43.
Check Out Our Latest Stock Analysis on GILD
Insider Activity at Gilead Sciences
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total value of $260,225.00. Following the sale, the chief financial officer now owns 169,061 shares of the company's stock, valued at $17,597,559.49. This represents a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 302,785 shares of company stock worth $30,540,875 over the last 90 days. Company insiders own 0.27% of the company's stock.
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
